Jasper Therapeutics, Inc. (JSPR)

NCM – Real Time Price. Currency in USD

0.34

-0.10 (-22.99%)

At close: Jun 26, 2026, 4:00 PM EDT

0.35

+0.01 (2.64%)

After-hours: Jun 26, 2026, 7:56 PM EDT

03.06.2026

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

01.06.2026

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.

14.05.2026

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.

30.03.2026

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update.

24.02.2026

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA.

08.01.2026

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

08.01.2026

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

Videos

No Data

There is no data to display

Press releases

01.06.2026

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

14.05.2026

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

30.03.2026

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

08.01.2026

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

Jasper Therapeutics, Inc. (JSPR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jasper Therapeutics, Inc. (JSPR)

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Videos

No Data

Press releases

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Videos

No Data

Press releases

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Search stocks

Jasper Therapeutics, Inc. (JSPR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jasper Therapeutics, Inc. (JSPR)

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Videos

No Data

Press releases

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Videos

No Data

Press releases

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria